Related Experiment Video
Updated: Nov 22, 2025
09:56
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
15.3K
Redox Responsive Polymersomes for Enhanced Doxorubicin Delivery.
Chetan Nehate1,2, Aradhana Nayal1,2, Veena Koul1,2
1Centre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India.
ACS Biomaterials Science & Engineering
|January 6, 2021
Summary
This study introduces novel, redox-sensitive polymersomes for enhanced doxorubicin (DOX) delivery. These nanostructures show improved tumor suppression and reduced toxicity, offering a promising cancer therapy alternative.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Doxorubicin (DOX) is a potent chemotherapy agent with significant cardiotoxicity.
- Developing targeted and safer drug delivery systems for DOX is crucial for improving cancer therapy efficacy and patient outcomes.
- Polymersomes offer a versatile platform for encapsulating therapeutic agents, potentially improving their pharmacokinetic profiles and reducing side effects.
Purpose of the Study:
- To explore the potential of a novel, self-assembled, biocompatible, and redox-sensitive copolymer system for doxorubicin (DOX) delivery.
- To evaluate the efficacy and safety of DOX-loaded polymersomes in preclinical cancer models.
- To assess the potential of these nanostructures for improved cancer treatment with reduced cardiotoxicity.
Main Methods:
- Synthesis of a novel redox-sensitive copolymer and formation of polymersome nanostructures (∼120 nm).
- In vitro and in vivo biocompatibility and cellular internalization studies in HeLa and MDA-MB-231 cell lines.
- Doxorubicin loading, colloidal stability assessment, cytotoxicity assays (MTT), tumor suppression studies in Ehrlich ascites tumor (EAT) bearing mice, and histopathology/serum biochemistry analysis.
Main Results:
- The copolymer system was synthesized with high yield (86%) and formed stable polymersomes.
- DOX-loaded polymersomes demonstrated excellent biocompatibility, enhanced cellular uptake, and dose-dependent cytotoxicity.
- In vivo studies showed a significant reduction in tumor volume (7.16-fold) and higher tumor inhibition (5.39-fold) compared to free DOX, with reduced associated toxicities.
Conclusions:
- The developed redox-responsive polymersomes are effective for targeted DOX delivery, exhibiting enhanced antitumor activity.
- These nanostructures show potential for safer DOX therapy, minimizing cardiotoxicity and offering a promising platform for clinical translation.
- The study highlights the therapeutic potential of biocompatible, self-assembled nanocarriers in improving chemotherapy outcomes.
